Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Connick P, Chandran S J Neurol Neurosurg Psychiatry. 2013 Nov; 84(11):e2. PMID: 24109005. Abstract CommentRecommendBookmarkWatch